The antimicrobial resistance crisis has become a significant threat to public health[@b1]. Globally, hospital outbreaks of infections caused by multi-drug resistant (MDR) Gram-negative pathogens, such as *Acinetobacter baumannii*, are being increasingly reported[@b2][@b3]. With few novel antibiotics in late-stage clinical development, clinicians may soon be left with no options for the treatment of recalcitrant infections caused by these MDR pathogens. *A. baumannii* has emerged as a particularly problematic pathogen, owing to its propensity to acquire resistance to most currently available antibiotics[@b4]. Polymyxins (*i.e.* polymyxin B and colistin) are used as a salvage therapy for *A. baumannii* infections where susceptibility testing suggests that carbapenems and aminoglycosides are unlikely to be effective[@b5][@b6][@b7]. Owing to their clinical introduction in the 1950s and fall from favour a decade or so later, the pharmacology of polymyxins has not been as thoroughly investigated as for modern antibiotics, until recently. While polymyxins demonstrate *in vitro* activity against many MDR *A. baumannii* bacterial isolates[@b3][@b8][@b9], reports of polymyxin-resistant *A. baumannii* clinical isolates[@b10] highlight an urgent need to investigate the influence of polymyxin dosage regimens on the emergence of resistance.

Polymyxins are cationic amphipathic compounds, containing a cyclic heptapeptide ring joined to a fatty acyl tail by a linear tripeptide. The L-2,4-diaminobutyric acid residues give rise to the cationic and hydrophilic nature of polymyxins, while the fatty acyl tail and position 6/7 amino acids of the heptapeptide ring contribute to the hydrophobicity of the compounds[@b11]. The aforementioned physicochemical properties of polymyxins are critical for their initial interaction with the negatively charged moieties and hydrophobic regions of lipid A of lipopolysaccharide (LPS) within the bacterial outer membrane (OM), leading to its permeabilisation[@b11]. While the interaction between lipid A and polymyxins is well characterised and essential for their ultimate bactericidal effect[@b11], the mechanism of polymyxin killing following perturbation of the OM has yet to be fully elucidated[@b12][@b13][@b14][@b15][@b16]. To date, two mechanisms of polymyxin resistance have been identified in *A. baumannii*: modification of lipid A with phosphoethanolamine and/or galactosamine and the complete loss of LPS from the OM[@b17][@b18][@b19][@b20][@b21]. Current literature suggests that both mechanisms of resistance abolish polymyxin-induced bacterial killing by preventing the interaction of polymyxins with the OM, and are mediated by the *pmrCAB* operon[@b17][@b21] (for lipid A modification with phosphoethanolamine), *naxD*[@b20] (for modification with galactosamine) or *lpx* biosynthetic cluster (for LPS loss)[@b19]. There is a paucity of knowledge on the emergence and mechanism(s) of resistance in response to the polymyxin exposure profiles associated with clinically relevant dosage regimens of colistin and polymyxin B.

The two clinically used polymyxins, colistin and polymyxin B, differ in their administered forms and exhibit markedly different clinical pharmacokinetics (PK)[@b5]. Colistin is administered parenterally as the sodium salt of its inactive pro-drug colistin methanesulphonate (CMS), while polymyxin B is available in the clinic as the sulphate salt of its active form. Following administration, CMS is converted slowly to colistin while simultaneously undergoing rapid renal elimination, which leads to a delay in the attainment of target colistin concentrations[@b22][@b23][@b24]. In contrast, the administration of polymyxin B enables target concentrations to be more rapidly achieved[@b25]. Although colistin and polymyxin B are considered equivalent based upon their antimicrobial activity *in vitro*[@b26], it was hypothesised that differences in their plasma concentration *versus* time profiles following initiation of therapy with CMS and polymyxin B, respectively, are likely to substantially affect their pharmacodynamic responses in patients. The objectives of this study were to investigate the transcriptomic profile and stability of polymyxin resistance in *A. baumannii* when exposed in an *in vitro* dynamic model to clinically relevant concentration *versus* time profiles of colistin and polymyxin B.

Methods
=======

Bacterial strain and media
--------------------------

*A. baumannii* strain AB307-0294, a previously characterised polymyxin-susceptible (MIC: 1.0 mg/L) clinical isolate belonging to international clonal complex I[@b27][@b28], was investigated in this study. Cation-adjusted Mueller-Hinton broth (CAMHB, Oxoid, Ca^2+^: 20--25 mg/L, Mg^2+^: 10--15 mg/L) was used in both the *in vitro* dynamic model and subsequent passaging. All bacterial cultures, including starter cultures and the *in vitro* model, were maintained at 37 °C for the duration of the experiment.

*In vitro* model and passaging in drug-free broth
-------------------------------------------------

A starting inoculum of 10^6^ CFU/mL of log-phase bacteria cultured from a single colony was introduced into a previously described *in vitro* one-compartment model (IVM). This model allows clinically relevant concentration *versus* time profiles of an antibiotic to be accurately achieved in a central reservoir inoculated with the organism of interest[@b29]. A total of 4 concentration-time profiles were simulated in the IVM ([Fig. 1](#f1){ref-type="fig"}) with a central reservoir volume of 250 mL. These profiles corresponded to: the gradual accumulation of colistin as would be seen at the initiation of CMS therapy with no loading dose[@b22] (regimen 1); 1-h polymyxin B infusion every 12 h without a loading dose (regimen 2); as for regimen 2 but with a loading dose to achieve the steady state immediately (regimen 3); and, regimen 2 initiated with an augmented loading dose to achieve concentrations over the first several hours higher than the eventual steady-state concentrations (regimen 4). Each regimen and the growth control were conducted in two replicates. For all regimens, an elimination half-life of 11.6 h was applied for both colistin and polymyxin B, representative of pharmacokinetic behaviour of both polymyxins in critically-ill patients[@b22][@b23][@b25][@b30]. For all four regimens an average steady-state concentration of 3 mg/L was simulated; for regimen 4, the augmented loading dose achieved a peak polymyxin B concentration of 6 mg/L after this initial dose and subsequently the concentrations declined to achieve the same steady-state profile as for the other two polymyxin B regimens ([Fig. 1](#f1){ref-type="fig"}). The elimination half-life and target polymyxin concentrations were selected to mimic the disposition of polymyxin B and colistin in critically-ill patients[@b22][@b25][@b23]. Samples (1 mL) were collected from the central reservoir at 0, 1, 8, 23, 28, 47, 52, 71 and 96 h, and numbers of viable bacteria were determined by plating onto drug-free agar plates. Population analysis profiles (PAPs) were obtained at 23, 47, 71 and 96 h by counting viable bacteria after plating cultures on polymyxin B containing agar plates (2, 4 and 8 mg/L as sulphate). At the conclusion of the IVM (96 h), polymyxin-resistant bacterial cells were isolated from each of the treated reservoirs (n = 8 total) and passaged daily for a further 96 h in drug-free CAMHB. PAPs were obtained daily on polymyxin B-containing (1, 2, 4 and 8 mg/L) agar plates.

Genomics and transcriptomics
----------------------------

Genomics samples were collected at the conclusion of passaging in drug-free CAMHB (192 h; consisting of 96 h in IVM and 96 h drug-free passaging) and DNA was prepared using a QIAamp DNA mini kit (Qiagen, USA) for high-throughput sequencing (150 bp paired-end reads). Transcriptomic profiling was performed on cultures recovered from each reservoir (n = 10; including growth control) at the conclusion of the IVM (96 h). Cultures collected for transcriptomic profiling (containing \~10^9^ CFU per sample) were centrifuged at 9000 × *g* (4 °C) for 10 min and resuspended in 1 mL of RNALater (Qiagen, USA) for 10 min before a second centrifugation at 5000 × *g* for 10 min, with the pellet stored at −80 °C prior to sequencing. Total RNA was purified from each sample (Qiagen RNeasy; Qiagen, USA), ribosomal RNAs removed (Ribo-Zero rRNA removal kit; Illumina, UK) and libraries prepared for RNA sequencing (100 bp single-end reads) as previously described[@b31]. DNA and RNA sequencing was performed on an Illumina HiSeq (Medical Genomics Facility, Monash Health Translation Precinct, Monash University, Victoria, Australia). RNA sequencing was performed over two Illumina HiSeq lanes, with replicates for each treatment condition analysed on separate lanes.

Next-generation sequencing data analysis
----------------------------------------

Illumina HiSeq reads for both genomic and transcriptomic analyses were clipped using the Nesoni software package (Victorian Bioinformatics Consortium) before mapping to a previously published[@b27] genome for *A. baumannii* AB307-0294 (Genbank accession: NC_011595) using the Short Read Mapping Package (SHRiMP 2.2.3). The average number of reads per sample was \~5 million for the genomic analysis, and \~23 million mapped reads per sample for transcriptomics analysis. Single nucleotide polymorphisms (SNPs) in the genomic and transcriptomic data were identified with Freebayes[@b32], using the previously published genome for *A. baumannii* AB307-0294 as a reference. Differential gene expression analysis of transcriptomic data was performed in Degust ([www.vicbioinformatics.com/degust](http://www.vicbioinformatics.com/degust)), a visual interface for the Voom and Limma R packages[@b33]. Statistical significance of differential gene expression was calculated using the F-statistic, jointly considering all treatment groups and adjusted using the Benjamini Hochberg method to control the false discovery rate (FDR)[@b34]. Differential expression was defined as a log~2~ fold-change (log~2~FC) of \>1.0 in any of the treatment groups relative to the growth control with a corresponding FDR of \<0.05. Interproscan[@b35] (version 5) was used for functional and gene ontology (GO) term annotation of the published *A. baumannii* AB307-0294 genome[@b27]. Principal component and GO term enrichment analyses (Fisher's exact test) were performed in R.

Integrated gene expression analysis for comparison of data from closely related strains
---------------------------------------------------------------------------------------

In addition to the conventional differential gene expression analysis, a sparse partial least squares regression discriminant analysis[@b36] (SPLS-DA) model was constructed to identify gene expression patterns that were (1) unique to the early stages of polymyxin exposure (≤1 h), and (2) shared between early- and late-stage polymyxin exposure (1 and 96 h). Matching of orthologous genes, defined as gene pairs with a p-value of \<10^−5^ when clustered using OrthoMCL[@b37], was used to merge data from the present study with a previously published transcriptomic dataset from *A. baumannii* strain ATCC 19606 sampled 15 and 60 min following colistin, doripenem, or colistin/doripenem combination treatment[@b31]. In total, 16 samples consisting of 5 untreated controls, 6 polymyxin-treated, 3 doripenem-treated and 2 combination-treated samples were used from the previously published dataset[@b31]. A variance stabilisation transformation was performed on the combined data in R using the DESeq2[@b38] package prior to SPLS-DA.

SPLS-DA model validation
------------------------

The SPLS-DA model was subjected to k-fold (k = 2) validation to select the smallest number of genes that optimally described the biological variation within the combined dataset. The combined data from the present study and our previous paper[@b31] were randomly partitioned into two segments (n = 13 each), with each segment used individually for model construction and the combined dataset used to determine the classification error rate (two tests per partitioning). The error rate for each candidate model was calculated as the average of 300 trials (600 tests) to account for the stochastic nature of partitioning. Candidate models contained between 10 and 150 genes (10 gene increments; 300 error rate trials per model) and were evaluated by their corresponding error rates. Once the smallest number of genes for inclusion had been determined, a second k-fold (k = 6; 6 tests per partitioning) validation was performed (50 trials; 300 tests total) to identify the inclusion rate of individual genes within models constructed on partitioned data sets.

Results
=======

Characterisation of polymyxin activity and resistance in *A. baumannii*
-----------------------------------------------------------------------

Polymyxin B dosage regimens that rapidly attained concentrations \>1 mg/L exhibited more bacterial killing compared to the simulated colistin dosing regimen ([Fig. 2A](#f2){ref-type="fig"}). The development of polymyxin resistance was phenotypically similar across all dosage regimens ([Fig. 2B](#f2){ref-type="fig"}). At the conclusion of polymyxin B or colistin treatment (96 h), bacterial cells isolated from the treated IVM reservoirs showed only a \~1--2 log~10~ CFU/mL difference between viable bacterial cells enumerated on drug-free and polymyxin-containing plates (8 mg/L), compared to the \~7 log~10~ CFU/mL difference seen in the controls at the same time point. Bacterial cells isolated from the control arms showed little change in polymyxin resistance profiles over the course of the IVM.

Drug-free passaging of the bacterial cells isolated from the polymyxin-treated reservoirs revealed the presence of stable (n = 2; one each from regimens 2 and 3) and non-stable (n = 6) polymyxin resistance ([Fig. 3](#f3){ref-type="fig"}). There was insufficient evidence to strongly link the development of stable polymyxin resistance with total polymyxin exposure or dosing intensity. Further, the proportion of resistant bacteria in stable resistant bacterial samples was unchanged between the commencement and conclusion of passaging (96 h) ([Fig. 3A](#f3){ref-type="fig"}). In the case of non-stable polymyxin resistance, partial reversion to susceptibility was extensive (\>2 log~10~ CFU/mL) but incomplete over 96 h of passaging ([Fig. 3B](#f3){ref-type="fig"}), with a \~2--3 log~10~ CFU/mL increase in viable counts on polymyxin-containing (8 mg/L) plates compared to the control.

Genomic analysis of the stable and non-stable polymyxin resistance phenotypes
-----------------------------------------------------------------------------

Interrogation of the genomes of the two stable polymyxin-resistant bacterial samples revealed a SNP in *pmrB* that led to a substitution of alanine at position 227 to valine (A227V). The same SNP was also found in the corresponding transcriptomic samples collected at the conclusion of polymyxin B or colistin treatment in the IVM, with \>96% of reads covering the affected base containing the SNP. In all but one of the bacterial samples with non-stable polymyxin resistance, examination of the transcriptome yielded no evidence of the *pmrB* A227V mutation or any other common genomic changes across the samples. However, in the case of one non-stable polymyxin-resistant bacterial sample treated with regimen 2, 90% of transcriptomic reads covering the affected base pairs contained the *pmrB* A227V SNP.

Transcriptomic analysis
-----------------------

In bacterial samples collected after polymyxin B or colistin treatment for 96 h in the IVM (polymyxin-resistant cultures), 33 genes showed increased expression and 28 showed decreased expression relative to the untreated control across the four different regimens ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}). Substantially increased expression (\>2-fold) of *AdeA* and *AdeB* (ABBFA_001707 and ABBFA_001708, respectively), members of the *AdeABC* multidrug efflux system, was observed in all polymyxin-treated samples. Similarly, increased expression of the genes encoding components of the Lol lipoprotein transport complex (ABBFA_000739 and ABBFA_000869) and the TolQRA transmembrane complex (ABBFA_000889, ABBFA_000888 and ABBFA_000382) was also evident. GO term enrichment analysis of genes exhibiting over-expression showed a statistically significant (FDR \< 0.05) over-representation of GO terms GO:0016020 (Cellular component: Membrane), GO:0005215 (Molecular function: Transporter activity), and GO:0006810 (Biological process: Transport). For the genes showing reduced expression in the presence of polymyxins, a common pattern of gene functions was less apparent, and was further confounded by the proportion of genes (12 out of 28 genes) identified as being hypothetical proteins. However, reduced expression was observed for six transcriptional regulators that have yet to be fully characterised in *A. baumannii*. No GO terms were found to be over-represented in the down-regulated gene set. Principal components analysis of transcriptomic profiles obtained at 96 h from the IVM revealed a high degree of separation between the control and polymyxin-treated (polymyxin B and colistin) samples ([Fig. 4](#f4){ref-type="fig"}). However, a clear relationship between the dosage regimen used and the transcriptomic profile observed was not evident.

SPLS-DA of multiple gene expression data sets
---------------------------------------------

The transcriptomic data from published experiments in *A. baumannii* ATCC 19606[@b31] were successfully merged and analysed with data from the current study. The validated model contained two components that included 10 and 50 genes, respectively. The early-stage transcriptomic response to polymyxin exposure was described by the first component of the SPLS model ([Table 3](#t3){ref-type="table"}), while commonalities between early- and late-stage responses to polymyxin exposure were characterised by the second model component ([Table 4](#t4){ref-type="table"}). Important predictors of early-stage polymyxin exposure in the SPLS model included genes involved in cellular metabolism (ABBFA_002620: Polyphosphate kinase, ABBFA_003493: NADPH-dependent FMN reductase family protein, ABBFA_002755: NAD^+^ synthetase) and protein mis-folding (ABBFA_002915: Peptidase C13 family protein). The genes common to early- and late-stage polymyxin exposure included seven efflux transporters (Resistance-Nodulation-Division \[RND\] family efflux transporters and multidrug resistance proteins A, B, and Y). Although these data are consistent with outer membrane perturbation, GO term enrichment analysis pointed to a statistically significant over-representation of only GO term GO:0009306 (Biological process: Protein secretion).

Discussion
==========

Given the worsening antimicrobial resistance crisis, there is an urgent need to further our understanding of the emergence of polymyxin resistance in *A. baumannii* and the association with the polymyxin exposure profile. *A. baumannii* AB307-0294, a multidrug-resistant clinical isolate from a bloodstream infection, has been genomically characterised[@b27] and represents an ideal model organism for mechanistic studies into polymyxin activity and resistance in *A. baumannii*. The present study indicates that the rapid and extensive bacterial killing associated with polymyxins was dependent on rapidly attaining therapeutic concentrations ([Fig. 2](#f2){ref-type="fig"}). Extensive polymyxin resistance was a common finding across all dosage regimens and reversion to susceptibility was substantial but incomplete during drug-free passaging in non-stable polymyxin-resistant bacterial samples ([Fig. 3](#f3){ref-type="fig"}). Notably, there was insufficient evidence in the transcriptomic profiles to identify a clear link between the dosage regimen employed and the transcriptomic responses associated with polymyxin resistance. Complex multi-level regulatory networks are likely involved in the development of polymyxin resistance and limit the utility of transcriptomics in isolation (*i.e.* in the absence of metabolomic and proteomic studies) to characterise the mechanisms that give rise to non-stable polymyxin resistance. Further, the clinical implications of these findings will require additional investigations using *in vivo* infection models and clinical studies that adequately account for the role of immune response in infection[@b39][@b40]. The *in vitro* data in the present study highlight the possible limitations of polymyxin monotherapy and the need for other strategies (e.g. combination therapy) for preventing the widespread emergence of polymyxin resistance[@b41].

In the present study, stable polymyxin resistance was caused by a previously documented *pmrB* A227V mutation[@b42], which is hypothesized to constitutively up-regulate *pmrCAB* operon expression[@b17][@b21]. The notable loss of polymyxin resistance during drug-free passaging in a sample found to contain the same *pmrB* A227V mutation implicates a fitness cost associated with the mutation. This is supported by previously published studies in *pmrB* A227V mutants of *A. baumannii* strain ATCC 19606, which discovered that the mutant displayed a slower growth rate compared to wild-type strains[@b42]. However, the development of non-stable resistance highlights that genetic mutations are unlikely to be the sole driver of polymyxin resistance. Our findings that the transcriptomic profiles of bacteria exhibiting stable and non-stable polymyxin resistance were highly similar indicate that the stable and non-stable resistance may share a common mechanism involving *pmrB*-mediated modification of lipid A. This finding is striking in light of the conspicuous absence of the PhoPQ -- PmrD signal transduction pathway in *A. baumannii* strains AB307-0294 and ATCC 19606. In other Gram-negative organisms, the PhoPQ two-component system is known to sense the presence of polymyxins and interfaces with PmrB *via* PmrD[@b43]. To date, an orthologous polymyxin sensing mechanism in *A. baumannii* has not been identified; there remains a pressing need to understand the role of polymyxin sensing and non-stable polymyxin resistance in determining the pharmacodynamics of polymyxin treatment in critically-ill patients.

While this study was limited to the examination of the transcriptome of *A. baumannii* strain AB307-0294, transcriptomic data from this study was successfully combined with previously published data characterising the early-stage responses to polymyxin exposure in *A. baumannii* ATCC 19606[@b31]. The combination of orthologous protein matching with SPLS-DA analysis enabled the integrated analysis of gene expression data between closely-related bacterial strains. SPLS-DA is a methodology developed to improve the analysis of high-dimensional omics datasets, combining multivariate statistics, dimension-reduction and feature selection[@b36]. This novel framework maximises the information gained from transcriptomics experiments by incorporating prior transcriptomic data. In this study, the fitted SPLS-DA model implicated the involvement of polyphosphate kinase (PPK; ABBFA002620) in the bacterial response to polymyxin exposure, a finding supported by studies in *Salmonella* that reported increased polymyxin susceptibility in Δ*PPK* mutants[@b44]. From these results, it can be hypothesised that the accumulation of inorganic polyphosphates is critical to the initial response to polymyxin exposure. Collectively, the altered expression of genes involved in cellular metabolism (ABBFA_003493: NADPH-dependent FMN reductase family protein, ABBFA_002755: NAD(+) synthetase) and PPK suggests that in the early stages of polymyxin exposure, the intracellular redox reactions are either directly disrupted by polymyxins or essential to the initial stress response following the exposure. Evidence of these disruptions has also been found in the metabolomes of colistin-treated *A. baumannii*[@b45]. Confirmation of the importance of these metabolic pathways on polymyxin activity and resistance using molecular techniques across a broader collection of *A. baumannii* strains will be crucial for identifying potential targets for novel antimicrobial agents.

GO term enrichment analysis, SPLS-DA, and a conventional analysis of gene expression showed remodelling of the OM to be a key aspect of polymyxin resistance; transcriptomic profiles obtained from *A. baumannii* strains AB307-0294 and ATCC19606 contained evidence of compensatory adaptations associated with OM remodelling. Increased expression of (RND) efflux transporter proteins (AdeABC and HlyD family) was a common finding across all analysis methodologies and stages of polymyxin exposure. This up-regulation of efflux transporters, observed in concert with over-expression of protein complexes involved in membrane homeostasis, supports previously published findings[@b31] that point to the diminished integrity and barrier function of the remodelled OM in polymyxin-treated *A. baumannii*. Polymyxins have been shown to exhibit synergistic activity in combination with other antibiotics such as carbapenems and chloramphenicol[@b46][@b47][@b48], and understanding polymyxin-induced OM remodelling will facilitate the development of rational antibiotic combination regimens that maximise bacterial killing and minimise the emergence of resistance.

Conclusions
===========

To our knowledge, this is the first study to investigate both the genomic and transcriptomic profiles of polymyxin resistance in *A. baumannii* following exposure to clinically relevant dosage regimens over an extended period. Unlike previous investigations into polymyxin resistance in Gram-negative organisms which focused on bacterial isolates that exhibit stable resistance, the present study reveals that both stable and non-stable polymyxin-resistant phenotypes are selected during treatment. Further, a framework for the integrative analysis of prior transcriptomic data from closely related bacterial strains revealed new insights into responses to polymyxins in *A. baumannii*. It remains to be elucidated the extent to which non-stable polymyxin resistance affects clinical outcomes. Our findings provide a foundation for understanding the mechanistic drivers of polymyxin resistance during polymyxin exposure resulting from clinically relevant dosage regimens, and highlight the importance of exploring optimised combination therapy in addressing the antimicrobial resistance crisis.
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![Viable counting results (mean ± SD; *n* = 2) for *A. baumannii* AB307-0294 samples grown on (**A**) drug-free agar plates and (**B**) polymyxin B containing (8 mg/L) agar plates.](srep26233-f2){#f2}

![Population analysis profiles (mean ± SD; (**A**) *n* = 2; (**B**) *n* = 6) of polymyxin-treated bacterial samples during passaging in drug-free CAMHB, showing stable polymyxin resistance (**A**) and the partial reversion (\>2 Log~10~ CFU/mL) to polymyxin susceptibility (**B**). Y-axis values reflect the difference in viable counts obtained on drug-free agar plates and polymyxin B containing agar plates at the concentrations indicated.](srep26233-f3){#f3}

![Principal components plots constructed from the transcriptomes of bacterial samples collected at the conclusion of the IVM.\
Arrows point to the samples exhibiting stable polymyxin resistance.](srep26233-f4){#f4}

###### Genes up-regulated in *A. baumannii* AB307-0294 following polymyxin treatment for 96 h in the IVM.

  Locus Tag      Published Annotation                                       Annotation by Similarity Searching (Hypothetical Proteins)   Dosage Regimen (log~2~ Fold-Change)                       
  -------------- --------------------------------------------------------- ------------------------------------------------------------ ------------------------------------- ------ ------ ------ -------
  ABBFA_000201   Succinate semialdehyde dehydrogenase                                                   --                                              1.64                   1.20   0.73   1.37   0.050
  ABBFA_000261   Hypothetical protein                                                             Signal peptide                                        3.48                   2.05   2.11   3.62   0.036
  ABBFA_000382   Protein TolA                                                                           --                                              3.43                   1.21   1.92   2.71   0.044
  ABBFA_000413   Hypothetical protein                                                    Toluene tolerance protein Ttg2E                                2.15                   0.79   1.11   1.56   0.049
  ABBFA_000570   TonB dependent receptor family protein                                                 --                                              1.69                   1.16   0.64   0.88   0.044
  ABBFA_000739   Outer membrane lipocarrier protein LolA                                                --                                              3.43                   1.18   2.01   2.74   0.044
  ABBFA_000816   Multidrug resistance protein mexB                                                      --                                              1.64                   0.48   0.76   1.18   0.044
  ABBFA_000869   Lipoprotein-releasing system transmembrane protein lolE                                --                                              1.78                   0.62   0.80   1.46   0.037
  ABBFA_000870   Lipoprotein releasing system, ATP-binding protein                                      --                                              1.83                   0.82   0.80   1.41   0.036
  ABBFA_000885   Peptidoglycan-associated lipoprotein                                                   --                                              1.25                   1.00   0.65   1.08   0.050
  ABBFA_000888   Protein TolR                                                                           \-                                              1.29                   0.52   0.63   1.08   0.044
  ABBFA_000889   Protein TolQ                                                                           --                                              1.12                   0.21   0.41   0.91   0.050
  ABBFA_000904   Hypothetical protein                                                               No matches                                          1.76                   1.06   0.82   1.42   0.044
  ABBFA_001022   Hypothetical protein                                                        Putative signal peptide                                    2.07                   0.97   1.17   1.72   0.050
  ABBFA_001302   Biofilm PGA synthesis protein pgaA precursor                                           --                                              2.58                   0.93   1.65   2.11   0.044
  ABBFA_001303   Biofilm PGA synthesis lipoprotein pgaB precursor                                       --                                              2.43                   1.01   1.40   1.95   0.044
  ABBFA_001304   IcaA                                                                                   --                                              2.25                   1.11   1.30   1.85   0.044
  ABBFA_001629   HTH-type transcriptional repressor Bm3R1                                               --                                              1.30                   0.58   0.38   1.22   0.044
  ABBFA_001662   HlyD family secretion family protein                                                   --                                              1.23                   1.19   0.58   0.93   0.050
  ABBFA_001663   Multidrug resistance protein Y                                                         --                                              1.84                   1.84   1.17   1.52   0.037
  ABBFA_001707   Acriflavine resistance protein E precursor                                             --                                              3.26                   3.42   2.07   3.26   0.028
  ABBFA_001708   AcrB protein                                                                           --                                              2.59                   2.59   1.36   2.45   0.036
  ABBFA_001709   Outer membrane protein oprM precursor                                                  --                                              1.51                   1.63   0.62   1.29   0.050
  ABBFA_001779   UTRA domain protein                                                                    --                                              0.01                   1.33   1.09   0.41   0.050
  ABBFA_002407   Hypothetical protein                                                        Putative signal peptide                                    1.62                   1.54   1.00   1.62   0.036
  ABBFA_002498   Putative phospholipid-binding domain protein                                           --                                              1.46                   0.57   0.79   1.36   0.050
  ABBFA_002880   Hypothetical protein                                                               No matches                                          0.75                   1.64   1.15   0.61   0.050
  ABBFA_003020   Outer membrane protein oprM precursor                                                  --                                              2.51                   1.46   1.11   1.78   0.036
  ABBFA_003050   phosphogluconate dehydratase                                                           --                                              1.45                   0.88   0.61   1.29   0.050
  ABBFA_003147   50S ribosomal protein L31 type B                                                       --                                              2.07                   1.71   1.20   1.39   0.037
  ABBFA_003406   AMP-binding enzyme family protein                                                      --                                              1.59                   0.89   0.87   1.88   0.050
  ABBFA_003500   Hypothetical protein                                                              Lipoprotein                                          3.28                   0.64   2.07   2.69   0.050
  ABBFA_003501   Hypothetical protein                                                              Lipoprotein                                          2.93                   1.35   1.94   3.22   0.037

###### Genes down-regulated in *A. baumannii* AB307-0294 following polymyxin treatment for 96 h in the IVM.

  Locus Tag      Published Annotation                                                   Annotation by Similarity Searching (Hypothetical Proteins)   Dosage Regimen (log~2~ Fold-Change)                          
  -------------- --------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------- ------- ------- ------- -------
  ABBFA_000133   Hypothetical protein                                                              Ribosomal subunit interface protein                              −1.05                  −1.84   −1.38   −1.87   0.044
  ABBFA_000218   Hypothetical protein                                                                           No matches                                          −1.47                  −1.99   −1.48   −1.28   0.036
  ABBFA_000426   Rrf2 family protein (transcriptional regulator) family protein                                     --                                              −1.70                  −2.32   −1.45   −1.81   0.045
  ABBFA_000555   Virulence sensor protein bvgS precursor                                                            --                                              −1.60                  −1.51   −1.36   −1.80   0.037
  ABBFA_000602   Hemolysin-3                                                                                        --                                              −1.56                  −2.07   −1.15   −1.73   0.038
  ABBFA_000699   PaaX-like family protein                                                                           --                                              −1.14                  −1.82   −1.06   −1.28   0.044
  ABBFA_000748   Hypothetical protein                                                                           No matches                                          −1.04                  −1.29   −1.19   −1.56   0.044
  ABBFA_000934   Hypothetical protein                                                                           No matches                                          −1.14                  −1.91   −1.17   −1.02   0.038
  ABBFA_000972   HTH-type transcriptional regulator gltR                                                            --                                              −2.04                  −2.22   −1.36   −1.89   0.050
  ABBFA_000981   CRISPR-associated protein Cas1                                                                     --                                              −1.90                  −2.65   −1.07   −1.27   0.047
  ABBFA_000982   CRISPR-associated helicase Cas3                                                                    --                                              −1.53                  −2.07   −1.12   −1.28   0.036
  ABBFA_000983   Hypothetical protein                                                             CRISPR-associated protein, Csy1 family                            −1.12                  −1.52   −0.96   −1.09   0.050
  ABBFA_001178   Hypothetical protein                                                                 Sulphur transfer protein SirA                                 −1.32                  −1.32   −0.67   −1.51   0.044
  ABBFA_001409   Benzoate membrane transport protein                                                                --                                              −0.94                  −1.77   −1.12   −1.44   0.050
  ABBFA_001469   Nitrogen regulation protein ntrB                                                                   --                                              −0.80                  −1.29   −0.76   −1.24   0.038
  ABBFA_001575   Hypothetical protein                                                                     Transporter component                                     −1.58                  −1.32   −1.47   −1.55   0.039
  ABBFA_001576   Hypothetical protein                                                                     Transporter component                                     −1.53                  −1.44   −1.52   −1.69   0.047
  ABBFA_001979   Hypothetical protein                                                                           No matches                                          −0.42                  −0.99   −0.80   −1.30   0.045
  ABBFA_002011   Tautomerase enzyme family protein                                                                  --                                              −0.81                  −1.70   −0.92   −1.21   0.037
  ABBFA_002314   Hypothetical protein                                                                          Lipoprotein                                          −1.08                  −1.23   −1.01   −1.11   0.050
  ABBFA_002503   Arginine exporter protein argO                                                                     --                                              −0.73                  −1.54   −0.71   −1.01   0.044
  ABBFA_002926   Hypothetical protein                                                                          Protein FilA                                         −0.88                  −1.14   −0.86   −1.14   0.050
  ABBFA_003141   Oxygen-independent coproporphyrinogen III oxidase-like protein yggW                                --                                              −0.89                  −1.02   −0.90   −1.16   0.044
  ABBFA_003359   Hypothetical protein                                                           TetR/AcrR family transcriptional regulator                          −1.90                  −2.19   −1.35   −1.77   0.044
  ABBFA_003360   Transcription regulatory protein opdE                                                              --                                              −2.62                  −2.41   −1.73   −2.40   0.050
  ABBFA_003361   AraC family transcriptional regulator                                                              --                                              −2.35                  −2.42   −1.50   −2.18   0.036
  ABBFA_003470   Linoleoyl-CoA desaturase (Delta(6)-desaturase)                                                     --                                              −3.91                  −3.67   −2.08   −3.84   0.037
  ABBFA_003471   Flavohemo (Hemoglobin-like protein)                                                                --                                              −4.32                  −3.92   −2.30   −3.98   0.044

###### Genes and their inclusion frequencies (10 most frequently included shown; 300 trials) in component 1 of the SPLS-DA model and corresponding expression levels.

  *A. baumannii* locus tags   Frequency of inclusion in SPLS-DA model    Annotated Product  log2-Fold Change *vs* Control                                    
  --------------------------- ----------------------------------------- ------------------- ------------------------------------------------ ------- ------- ----------
  ABBFA_002620                HMPREF0010_01526                                 63.7%        Polyphosphate kinase                              −1.10   0.80    1.79E-09
  ABBFA_003493                HMPREF0010_03371                                 57.3%        NADPH-dependent FMN reductase family protein      1.67    −0.40   1.90E-10
  ABBFA_000791                HMPREF0010_02052                                 56.0%        FtsJ-like methyltransferase family protein        0.68    −0.33   1.68E-08
  ABBFA_003446                HMPREF0010_03271                                 50.0%        Phosphomannomutase (PMM)                          1.65    −0.31   3.70E-11
  ABBFA_002750                HMPREF0010_01358                                 42.7%        Hypothetical protein                              1.13    −0.59   4.00E-10
  ABBFA_002755                HMPREF0010_01353                                 42.7%        Probable glutamine-dependent NAD(+) synthetase    1.00    −0.13   9.09E-10
  ABBFA_002915                HMPREF0010_01204                                 33.7%        Peptidase C13 family protein                      0.74    −0.28   1.79E-08
  ABBFA_003004                HMPREF0010_01698                                 32.3%        Hypothetical protein                              1.12    −0.12   1.14E-09
  ABBFA_002591                HMPREF0010_01555                                 32.3%        Protein hupE precursor                            −0.52   0.83    1.16E-08
  ABBFA_000299                HMPREF0010_02497                                 30.7%        Cobalt-zinc-cadmium resistance protein czcD       0.62    −0.44   1.97E-07

Component 1 of the SPLS-DA model described gene expression profiles unique to early-stage polymyxin exposure.

###### Genes and their inclusion frequencies (Genes included in \>50% of models shown; 300 trials) in component 2 of the SPLS-DA model (over 300 trials) and corresponding expression levels.

  *A. baumannii* Locus Tags   Frequency of Inclusion in SPLS-DA Model           log2-Fold Change *vs* Control                                                          
  --------------------------- ----------------------------------------- ------- ---------------------------------------------------------------------- ------- ------- ----------
  ABBFA_003136                HMPREF0010_01842                           78.7%  Long-chain-acyl-CoA synthetase                                          1.13    1.51    1.68E-08
  ABBFA_001663                HMPREF0010_00531                           77.3%  Multidrug resistance protein Y                                          1.30    1.73    4.11E-08
  ABBFA_002953                HMPREF0010_01645                           77.3%  Acetyl-CoA carboxylase, carboxyl transferase, alpha subunit             −1.61   −1.73   9.23E-09
  ABBFA_000610                HMPREF0010_02771                           76.7%  AraC family transcriptional regulator                                   −1.10   −1.42   2.34E-08
  ABBFA_000999                HMPREF0010_02246                           76.7%  Linoleoyl-CoA desaturase (Delta(6)-desaturase)                          −1.77   −1.93   1.71E-07
  ABBFA_001662                HMPREF0010_00530                           75.7%  HlyD family secretion family protein                                    0.72    1.27    2.10E-06
  ABBFA_000369                HMPREF0010_02566                           74.7%  CobQ/CobB/MinD/ParA nucleotide binding domain protein                   −0.75   −1.00   2.38E-06
  ABBFA_002706                HMPREF0010_01403                           74.7%  Multidrug resistance protein B                                          1.51    1.89    1.16E-06
  ABBFA_002838                HMPREF0010_01276                           73.3%  HlyD family secretion family protein                                    1.36    1.58    1.83E-06
  ABBFA_003296                HMPREF0010_01991                           71.7%  Response regulator                                                      −0.84   −1.17   2.81E-07
  ABBFA_003340                HMPREF0010_02034                           71.3%  Hypothetical protein                                                    1.57    2.20    7.38E-05
  ABBFA_001460                HMPREF0010_00336                           70.3%  Hypothetical protein                                                    −1.20   −1.42   1.41E-06
  ABBFA_001969                HMPREF0010_00851                           69.0%  Biotin synthase                                                         −1.11   −1.75   2.84E-08
  ABBFA_002943                HMPREF0010_01635                           68.3%  Transcriptional regulator OhrR                                          −0.85   −1.10   5.16E-06
  ABBFA_000374                HMPREF0010_02571                           68.0%  Hypothetical protein                                                    −1.50   −2.12   2.84E-07
  ABBFA_002707                HMPREF0010_01402                           68.0%  Multidrug resistance protein A                                          1.55    1.97    5.16E-06
  ABBFA_001415                HMPREF0010_00288                           67.3%  3-ketoacyl-(acyl-carrier-protein) reductase                             1.91    1.77    1.94E-07
  ABBFA_002751                HMPREF0010_01357                           66.3%  Beta-ketoacyl synthase, N-terminal domain protein                       −1.17   −1.74   1.16E-07
  ABBFA_003341                HMPREF0010_02035                           63.3%  Flavoprotein wrbA (Trp repressor-binding protein)                       1.78    1.76    5.88E-05
  ABBFA_000033                HMPREF0010_03386                           62.7%  Efflux transporter, RND family, MFP subunit                             1.49    1.57    3.91E-06
  ABBFA_000205                HMPREF0010_02441                           62.3%  Hypothetical protein                                                    −1.30   −2.46   6.42E-09
  ABBFA_002898                HMPREF0010_01218                           61.7%  Sorbitol dehydrogenase                                                  1.24    1.60    2.86E-05
  ABBFA_002836                HMPREF0010_01278                           60.3%  TetR family regulatory protein                                          2.28    1.71    5.54E-08
  ABBFA_001549                HMPREF0010_00427                           57.7%  2,4-dienoyl-CoA reductase \[NADPH\](2,4-dienoyl coenzymeA reductase)    1.03    2.25    7.05E-06
  ABBFA_002613                HMPREF0010_01533                           54.3%  Hypothetical protein                                                    −0.87   −1.66   7.02E-07
  ABBFA_000601                HMPREF0010_02763                           52.0%  MFS transporter, metabolite:H+ symporter (MHS) family protein           −0.59   −0.69   5.28E-05
  ABBFA_000867                HMPREF0010_02122                           52.0%  Hypothetical protein                                                    −0.43   −0.71   3.25E-05
  ABBFA_000206                HMPREF0010_02442                           51.7%  Methyltransferase domain protein                                        −0.83   −1.45   6.02E-06
  ABBFA_003085                HMPREF0010_01789                           51.7%  Coniferyl aldehyde dehydrogenase (CALDH)                                −1.23   −1.60   3.22E-06
  ABBFA_000998                HMPREF0010_02245                           51.3%  Phthalate dioxygenase reductase (PDR)                                   −2.06   −1.88   2.64E-06

Component 2 of the SPLS-DA model described gene expression profiles common to early- and late-stage polymyxin exposure.
